SLC47A2 antibody
- Known as:
- SLC47A2 (anti-)
- Catalog number:
- orb125139
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- SLC47A2 antibody
Related genes to: SLC47A2 antibody
- Gene:
- SLC47A2 NIH gene
- Name:
- solute carrier family 47 member 2
- Previous symbol:
- -
- Synonyms:
- FLJ31196, MATE2, MATE2-K
- Chromosome:
- 17p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 2007-05-18
- Date modifiied:
- 2016-02-17
Related products to: SLC47A2 antibody
Related articles to: SLC47A2 antibody
- Platinum-based chemotherapeutics remain clinically indispensable for treating various malignancies despite causing severe side effects, with ototoxicity being particularly limiting. This study reports the synthesis and evaluation of platinum(IV) prodrugs incorporating the hearing-protective ligand RG108. Among the synthesized mono- and di-substituted cisplatin and oxaliplatin derivatives, compound 4 exhibited exceptional antitumor activity with an IC value of 0.07 ± 0.08 µM in FaDu cells. Mechanistic investigations revealed that the enhanced anti-tumor effect was primarily mediated via the EZH2/SLC47A2 regulatory axis. These prodrugs significantly mitigated ototoxicity, preserving cochlear hair cell viability, stabilizing auditory brainstem response thresholds, and maintaining cochlear basement membrane morphology. Our findings establish a framework for designing dual-functional platinum agents that synergize antitumor efficacy with organoprotective properties, addressing critical hearing loss limitations of conventional platinum chemotherapy while maintaining robust therapeutic outcomes. - Source: PubMed
Publication date: 2026/03/12
Wu JiyongNie JingWu HuinaWang DongboLi YameiLiang MinyanQian HuimeiWang Yong - Diabetes type 2 (DT2) entails significant health, economic, and productivity repercussions around the world. Poor glycaemic control, defined as an HbA1c >7.0%, has been associated with a number of complications. In spite of the large share of healthcare resources allocated to DT2 treatment, the proportion of controlled Mexican patients is among the lowest in the world (34.4%). Certain protein-encoding genetic polymorphisms involved in metformin transport may affect glycaemic control. We focused on determining the frequency of rs2289669, rs2252281, rs12943590, and rs34834489 polymorphisms in Mexican-Mestizo patients from the Tertiary Care Regional Hospital of Ixtapaluca, State of Mexico, Mexico, as well as assessing their possible association with therapeutic efficacy, as estimated through glycated haemoglobin. The individual polymorphism analysis did not reveal an association with glycaemic control; however, when combined with rs72552763 and rs622342, we found a significant positive correlation between HbA1c levels and metformin dose, which prevailed among patients carrying allelic variants of rs2289669 or rs12943590 who were also simultaneously carrying allelic variants of rs72552763 or rs622342. Patients carrying the reference allele of rs34834489 reported a significant positive correlation between HbA1c levels and metformin dose as well, regardless of their rs72552763 or rs622342 genotype. Thus, we identified alleles and allelic combinations of , , and polymorphisms posing a potential glycaemic control risk in Mexican-Mestizo patients. - Source: PubMed
Publication date: 2025/09/05
Gómez-Hernández Milton AbrahamOrtega-Ayala AdielRodríguez-Lima OscarLanda AbrahamAcosta-Altamirano GustavoMolina-Guarneros Juan A - This study explores the relationship between gene polymorphisms and glycemic responses across ethnic populations and identifies optimal therapy combinations for glycemic control. However, the definition of glycemic response varied across included studies (e.g., HbA1c <7 %, or >0.5 % reduction), which may affect the comparability and interpretation of pooled data. - Source: PubMed
Publication date: 2025/06/24
Ahmad FikryAbubakar SuhailiSyed Alwi Sharifah SakinahChuan Ng Ooi - The multidrug and toxin extrusion proteins MATE1 and MATE2K may determine the pharmacokinetics and drug-drug interactions of many drugs. However, their substrate spectrum and synergy with organic cation transporters OCT1 and OCT2 remain incompletely understood. Therefore, we screened 590 predominantly positively charged, low molecular weight compounds for transport via these four transporters in HEK293 cells using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). MATE1 and MATE2K transported 164 and 114 compounds, respectively, with significant overlap. High-affinity substrates included berberine, pentamidine, and amisulpride, while epinephrine and atenolol had the highest . Despite less than 16% sequence homology, there was high overlap among MATE1/-2K and OCT1/-2 substrates. Neither isolated physicochemical properties nor their linear combinations predicted the substrates of these organic cation transporters. However, machine learning classifiers using 15 parameters allowed 69 to 87% correct prediction. The large number of substrates indicates a possibly broad role of multidrug and toxin extrusion (MATE) transporters in pharmacokinetics and drug interactions. - Source: PubMed
Publication date: 2025/06/13
Redeker Kyra-Elisa MariaKirsch NicolaiBoretius SusannTzvetkov MladenBrockmöller Jürgen - With growing interest in a biomarker-based approach for drug-drug interaction (DDI) predictions, creatinine, N1-methylnicotinamide (NMN), and N1-methyladenosine (mA) have been identified as endogenous substrates of organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) 1/2-K, though clinical validation remains limited. This study builds on recent advancements by evaluating these biomarkers retrospectively using samples from a clinical pharmacology study that assessed DDI via renal cationic transporters between fedratinib (inhibitor) and metformin (substrate) in healthy participants. Fedratinib reduced renal clearance for all endogenous substrates, with mA (38 %) and NMN (36 %) showing reductions comparable to metformin (40 %), while creatinine exhibited slightly lower (29 %), likely reflecting its limited contribution to transporter-mediated renal tubular secretion. Simulations focused on mA due to its favorable characteristics over NMN, particularly its minimal diurnal and intra-participant variability, demonstrating that reliable DDI assessments can still be achieved despite sampling constraints typical in oncology settings. Collectively, our study supports the predictive capabilities of endogenous substrates as biomarkers for renal cation transporter inhibition, with mA in particular showing promise for early DDI assessments in the Phase 1 studies. - Source: PubMed
Publication date: 2025/05/30
Nishii RinaXue YongjunHuo RunlanChen JianShen HongChen YizheOgasawara Ken